EmphyCorp has been granted eight U.S. patents and three additional are pending with respect to its new drug, "N115". Until now the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases is the use of corticosteroids (67%). It is well documented that prolonged use of corticosteroids for the treatment of pulmonary diseases has serious side effects including death. Other marketed drugs for the treat...
EmphyCorp has been granted eight U.S. patents and three additional are pending with respect to its new drug, "N115". Until now the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases is the use of corticosteroids (67%). It is well documented that prolonged use of corticosteroids for the treatment of pulmonary diseases has serious side effects including death. Other marketed drugs for the treatment of pulmonary diseases can produce central nervous system, cardiovascular, respiratory and gastrointestinal problems.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.